Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment

Journal of Bone and Mineral Research

Volumn 24, Issue 6, 2009, Pages 1125-1131

  Watts, Nelson B ^a   Miller, Paul D ^b   Kohlmeier, Lynn A ^c   Sebba, Anthony ^d   Chen, Peiqi ^e   Wong, Mayme ^e   Krohn, Kelly ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b University of Colorado Health Sciences Center   (United States)

^c Spokane Medical Centers   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Amino terminal extension peptide of procollagen type I; BMD; Bone turnover; Femoral neck; Fracture; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SPINE RADIOGRAPHY; TREATMENT RESPONSE; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE REMODELING; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; HUMANS; MIDDLE AGED; PLACEBOS; RISK FACTORS; SPINAL FRACTURES; TERIPARATIDE;

EID: 66349087349     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081256     Document Type: Article

References (29)

1. Miller PD 2007 Monitoring osteoporosis therapies. Curr Osteoporos Rep 5:38-43. (Pubitemid 46447930)
2. Sebba AI 2008 Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther 30:443-452.
3. Lewiecki EM, Watts NB 2008 Assessing response to osteoporosis therapy. Osteoporos Int 19:1363-1368.
4. Diez-Perez A, Gonzalez-Macias J 2008 Inadequate responders to osteoporosis treatment: Proposal for an operational definition. Osteoporos Int 19:1511-1516.
5. Lewiecki EM 2003 Nonresponders to osteoporosis therapy. J Clin Densitom 6:307-314. (Pubitemid 38114506)
6. Chapurlat RD, Palermo L, Ramsay P, Cummings SR 2005 Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 16:842-848.
7. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441.
8. Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R 2006 Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 39:1268-1275. (Pubitemid 44827926)
9. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148. (Pubitemid 23261108)
10. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970. (Pubitemid 40712820)
11. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY 2006 Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66. (Pubitemid 43106908)
12. Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19:623-629. (Pubitemid 41071223)
13. Hirano T, Burr DB, Cain RL, Hock JM 2000 Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int 66:456-460. (Pubitemid 30368377)
14. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16:157-165.
15. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941.
16. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543. (Pubitemid 36241071)
17. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768. (Pubitemid 41138965)
18. Seeman E 2007 Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy? Bone 41:308-317.
19. Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236. (Pubitemid 32268819)
20. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246-1254. (Pubitemid 29268962)
21. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281-289. (Pubitemid 34219441)
22. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1-10. (Pubitemid 33150990)
23. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261. (Pubitemid 39178892)
24. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 21:1785-1790. (Pubitemid 46141234)
25. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis. Excerpta Medica, Belle Mead, NJ, USA.
26. Carey JJ 2005 What is a 'failure' of bisphosphonate therapy for osteoporosis? Cleve Clin J Med 72:1033-1039.
27. Bonnick SL, Johnston CC Jr, Kleerekoper M, Lindsay R, Miller P, Sherwood L, Siris E 2001 Importance of precision in bone density measurements. J Clin Densitom 4:105-110. (Pubitemid 32643312)
28. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU 1990 Predicting femoral neck strength from bone mineral data. A structural approach. Invest Radiol 25:6-18.
29. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM 2008 Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by Finite Element Analysis of Quantitative CT scans. J Bone Miner Res 23:1974-1982.